MX2019010833A - Complejos para el tratamiento de la sensibilidad. - Google Patents

Complejos para el tratamiento de la sensibilidad.

Info

Publication number
MX2019010833A
MX2019010833A MX2019010833A MX2019010833A MX2019010833A MX 2019010833 A MX2019010833 A MX 2019010833A MX 2019010833 A MX2019010833 A MX 2019010833A MX 2019010833 A MX2019010833 A MX 2019010833A MX 2019010833 A MX2019010833 A MX 2019010833A
Authority
MX
Mexico
Prior art keywords
complexes
amorphous calcium
stannous
phosphate
per mole
Prior art date
Application number
MX2019010833A
Other languages
English (en)
Inventor
Charles Reynolds Eric
Original Assignee
Univ Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900892A external-priority patent/AU2017900892A0/en
Application filed by Univ Melbourne filed Critical Univ Melbourne
Publication of MX2019010833A publication Critical patent/MX2019010833A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A61K8/21—Fluorides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/58—Metal complex; Coordination compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a complejos de fosfato de calcio amorfo estabilizado con fosfopeptido y/o complejos de fosfato de fluoruro de calcio amorfo mejorados y composiciones que contienen esos complejos. Tambien se proporcionan metodos para fabricar los complejos de la invencion y para el tratamiento de la hipersensibilidad dental. En una modalidad, la invencion proporciona un complejo de fosfato de calcio amorfo (ACP) estabilizado con fosfopeptido asociado a estano (PP) o complejo de fosfato de fluoruro de calcio amorfo (ACFP) que tiene un contenido de iones estanosos igual o mayor que 1 mol de estano por mol de PP pero menos de 4 moles de estano por mol de PP.
MX2019010833A 2017-03-14 2018-03-14 Complejos para el tratamiento de la sensibilidad. MX2019010833A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017900892A AU2017900892A0 (en) 2017-03-14 Complexes for treating sensitivity
PCT/AU2018/050230 WO2018165707A1 (en) 2017-03-14 2018-03-14 Complexes for treating sensitivity

Publications (1)

Publication Number Publication Date
MX2019010833A true MX2019010833A (es) 2019-10-30

Family

ID=63521649

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010833A MX2019010833A (es) 2017-03-14 2018-03-14 Complejos para el tratamiento de la sensibilidad.

Country Status (15)

Country Link
US (1) US20200197486A1 (es)
EP (1) EP3595630A4 (es)
JP (1) JP7138352B2 (es)
KR (1) KR102555722B1 (es)
CN (1) CN110475539A (es)
AU (1) AU2018233576B2 (es)
BR (1) BR112019018871A2 (es)
CA (1) CA3055086A1 (es)
EA (1) EA201991935A1 (es)
MX (1) MX2019010833A (es)
MY (1) MY201505A (es)
NZ (1) NZ757004A (es)
PH (1) PH12019550156A1 (es)
SG (1) SG11201907950VA (es)
WO (1) WO2018165707A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9668945B2 (en) 2006-02-09 2017-06-06 The University Of Melbourne Fluoride composition and methods for dental mineralization
CA2918441C (en) 2013-07-23 2023-03-21 The University Of Melbourne A base and phosphopeptide stabilized amorphous calcium phosphate (acp) and/or amorphous calcium fluoride phosphate (acfp) for use in promoting remineralisation
WO2015095932A1 (en) 2013-12-24 2015-07-02 The University Of Melbourne Stabilized stannous compositions
EP3595615B1 (en) 2017-03-14 2024-01-10 The University Of Melbourne Treatment for gingivitis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447732A (en) * 1992-11-25 1995-09-05 Ajinomoto Co., Inc. High-absorption mineral-containing composition and foods
CA2469498C (en) * 2002-01-03 2009-06-02 The Procter & Gamble Company Stable oral compositions comprising casein phosphopeptide complexes and fluoride
JP2005145952A (ja) 2003-10-23 2005-06-09 Gc Corp う蝕予防用組成物
WO2009099455A1 (en) * 2008-02-08 2009-08-13 Colgate-Palmolive Company Oral care product and methods of use and manufacture thereof
JP4693191B2 (ja) 2009-08-06 2011-06-01 日本歯科薬品株式会社 口腔用剤
JP2011073983A (ja) * 2009-09-29 2011-04-14 Gc Corp 歯牙塗布用組成物
JP2011162470A (ja) * 2010-02-09 2011-08-25 Gc Corp 歯牙用被覆材
WO2014050144A1 (ja) 2012-09-28 2014-04-03 江崎グリコ株式会社 象牙細管封鎖剤
WO2015095932A1 (en) * 2013-12-24 2015-07-02 The University Of Melbourne Stabilized stannous compositions
CN104001157B (zh) * 2014-05-27 2015-12-02 高益槐 一种防治骨质疏松症的复方制剂及其制备方法
RU2720242C2 (ru) * 2014-12-24 2020-04-28 Юниверсити Оф Мельбурн Минерализующие фторсодержащие композиции
EP3595615B1 (en) * 2017-03-14 2024-01-10 The University Of Melbourne Treatment for gingivitis

Also Published As

Publication number Publication date
BR112019018871A2 (pt) 2020-04-14
CA3055086A1 (en) 2018-09-20
WO2018165707A1 (en) 2018-09-20
US20200197486A1 (en) 2020-06-25
JP7138352B2 (ja) 2022-09-16
SG11201907950VA (en) 2019-09-27
EP3595630A1 (en) 2020-01-22
MY201505A (en) 2024-02-27
NZ757004A (en) 2023-05-26
EP3595630A4 (en) 2021-01-13
JP2020514351A (ja) 2020-05-21
KR20190126134A (ko) 2019-11-08
AU2018233576A1 (en) 2019-09-26
KR102555722B1 (ko) 2023-07-13
PH12019550156A1 (en) 2020-03-16
CN110475539A (zh) 2019-11-19
AU2018233576B2 (en) 2021-06-24
EA201991935A1 (ru) 2020-02-14

Similar Documents

Publication Publication Date Title
PH12019550156A1 (en) Complexes for treating sensitivity
MX2023003470A (es) Anticuerpo anti-garp.
MY201925A (en) Macrocyclic compounds and uses thereof
MX2016015772A (es) Composiciones orales que contienen fuentes de ion de zinc, estaño y fluoruro.
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
MX2019002211A (es) Composiciones de nicotinamida ribosido y pterostilbeno y metodos para el tratamiento de trastornos neurodegenerativos.
PH12016501732A1 (en) Formulation for soft anticholinergic analogs
EP3659611A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF OSTEOPOROSIS WITH EXOSOMES EXTRACTED FROM STEM CELLS AS THE ACTIVE SUBSTANCE
PH12016501218A1 (en) Stabilized stannous compositions
MY195081A (en) Pladienolide Pyridine Compounds and Methods of use
MX2018014969A (es) Una composicion para el cuidado bucal.
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
NZ761519A (en) Nlrp3 modulators
MX2017002388A (es) Composiciones para fibras de queratina.
PH12019550157A1 (en) Treatment for gingivitis
MX2017013047A (es) Tratamiento de dolor.
EP4218789A3 (en) Compositions for colon cleansing and the treatment of gastrointestnal disorders
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
MX2015001344A (es) Producto novedoso de leche fermentada y metodo para preparar el mismo.
MY167428A (en) Novel fermented milk product and method for producing the same
MX2020008082A (es) Compuestos y composiciones para el tratamiento del dolor.
MX2017013669A (es) Composiciones para el tramiento del cancer.
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
PH12015500052A1 (en) Novel powdered milk product and method for producing the same